share_log

Laidlaw & Co. Initiates Coverage On Evofem Biosciences with Buy Rating, Announces Price Target of $3.5

Benzinga Real-time News ·  Jun 2, 2022 09:30

Laidlaw & Co. analyst Yale Jen initiates coverage on Evofem Biosciences (NASDAQ:EVFM) with a Buy rating and announces Price Target of $3.5.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment